login
login

Europe Daily Bulletin No. 12695

10 April 2021
Contents Publication in full By article 1 / 26
EU RESPONSE TO COVID-19
HEALTH: Johnson & Johnson vaccine’s turn to come under scrutiny at European Medicines Agency for blood clots
Brussels, 09/04/2021 (Agence Europe)

The European Medicines Agency (EMA) announced, on Friday 9 April, that an investigation had been opened by its safety committee (PRAC) to assess the risks of thromboembolic events linked to the Covid-19 vaccine produced by the pharmaceutical company Janssen Pharmaceutica NV, a Belgian subsidiary of the US group Johnson & Johnson.

The PRAC “has started a review of a safety signal”: in other words, the reports it has received about these thromboembolic events (blood clots, leading to the...

Contents

EU RESPONSE TO COVID-19
EXTERNAL ACTION
SECTORAL POLICIES
FUNDAMENTAL RIGHTS - SOCIETAL ISSUES
COUNCIL OF EUROPE
ECONOMY - FINANCE - BUSINESS
NEWS BRIEFS
CALENDAR
CALENDAR EXTRA